Teaching Hospital of Chengdu University of Traditional Chinese Medicine
Chengdu, Sichuan, 610000, China
NCT Number: NCT04272476
This study evaluates the activation on prefrontal cortex with acupuncture and moxibustion for major depressive disorder.Half of participants will receive the treatment of acupuncture and moxibustion, while the other participants will receive the fluoxetine.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Chengdu, Sichuan, 610000, China
Major depressive disorder (MDD) is a psychiatric condition with high morbidity, disability, suicide and recurrence rate and become the hot and difficult topics in the medical study. Given the unsatisfactory response rates of many FDA-approved antidepressants, acupuncture is increasingly considered an important alternative therapy. A large number of clinical trials have confirmed that acupuncture is a generally safe, effective, and well-tolerated therapy for depression, but for MDD, the acupuncture clinical trials were only reported out of China. According to the clinical symptoms in patients with MDD, the chief TCM patterns are liver qi constraint and heart yang insufficiency, and the secondary TCM patterns are blood stasis, qi and blood deficiency. So we propose to combine acupuncture with moxibustion and select Baihui (DU20), shenting(DU24), Neiguan (PC6), Hegu (LI4), Taichong (LV3), Zusanli(ST36), Zhongwan (RN 12) and Gaunyuan (RN4) to Soothe the Liver, regulating the heart, warm the yang qi, boost qi and invigorate blood for MDD. We hypothesize that the acupuncture's antidepressant effect is based on the neural network reconstructing mechanism through studying the cerebral cortex function, hippocampal synaptic plasticity, Neurons electrophysiological change. We will employ multi-disciplinary methods in neuropsychology, neuroimaging, computer science, and electrophysiology to explore the important mechanism underlying acupuncture and moxibustion treating MDD.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Other names: Prozac
Time frame: 1, 2, 4, 6, 8 weeks after treatment
Evaluating the patient's depressive degree
Time frame: 1, 2, 4, 6, 8 weeks after treatment
Evaluating the patient's prefrontal oxyhemoglobin
Time frame: Screening criteria
Chengdu University of Traditional Chinese Medicine
Other
The Activation on Prefrontal Cortex With Acupuncture and Moxibustion for Major Depressive Disorder: A Study of Functional Near Infrared Spectroscopy (ACUfNIRS)
Acronym: ACUfNIRS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05680727
Behavior, Behavioral Symptoms
Boston, Massachusetts, United States
View Trial DetailsNCT07258485
Depressive Disorder, Depressive Disorder, Major
Phoenix, Arizona, United States
View Trial DetailsNCT06558344
Depressive Disorder, Depressive Disorder, Major
Bellflower, California, United States
View Trial DetailsNCT04533529
Depressive Disorder, Depressive Disorder, Major
Anaheim, California, United States
View Trial Details